Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease
Voyager Therapeutics announced upcoming presentations at ASGCT 2026, featuring preclinical data for its lead Alzheimer's candidate VY1706. A late-breaking presentation will highlight 3-month GLP toxicology data for VY1706, demonstrating safety and pharmacology that supports an anticipated IND filing in Q2 2026 and first-in-human dosing in the second half of the year.
Key figures
- Drug Name
- VY1706
- Phase Of Trial
- GLP toxicology study (pre-IND)
- Ind timing fy
- Q2 2026
- Presentation count
- 8
- First in human dosing
- second half of 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.